Skip to content
Sign inOpen the app
BioSpace

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

July 15 · 21 min · 41.0 MB
0:00-21:22

Streams straight from the publisher. podnod never proxies or re-hosts episode audio.

Open in podnodTranscript

Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.